Cameroon has taken custody of its first shipment of Mosquirix malaria vaccines manufactured by British drugmaker, GSK Plc.
Following trial programmes in Ghana, Kenya, and Malawi, a batch of 331,200 doses of the vaccine—also known as RTS, S—was offloaded at Yaounde’s Nsimalen International Airport, making Cameroon one of the first nations in Africa to receive the shot.
Cameroon’s health minister, Manaouda Malachie announced that 42 of the 203 health districts in the nation would receive the first shipment of vaccines.
“We lose many compatriots who die because of this disease. Today, we have a vaccine which comes to add to the panoply of measures already rolled out,” Malachie told reporters at Nsimalen.
According to GSK, the vaccine has already been administered to over 1.7 million children in Ghana, Kenya, and Malawi, and will begin to be administered in nine more malaria-endemic nations, including Cameroon. In a joint statement with WHO and UNICEF, the global vaccine alliance, GAVI announced that an additional 1.7 million doses of the RTS,S vaccine were anticipated to arrive in Burkina Faso, Liberia, Niger, and Sierra Leone in the upcoming weeks.
By 2026, 40–60 million doses of the malaria vaccine will be required annually, and by 2030, 80–100 million doses will be required, according to estimates from the WHO, UNICEF, and Gavi.
Malaria is a disease caused by a parasite. The parasite is spread to humans through the bites of infected mosquitoes. In 2021, 96 percent of the world’s malaria deaths occurred in Africa.